Table 2.
Efficacies of the neoadjuvant/conversion treatment
| Total (n = 25) | cT4aN+ (n = 11) | cT4bN+ (n = 14) | |
|---|---|---|---|
| Tumor down-staging rate | 76.0% (19/25) | 81.8% (9/11) | 71.4% (10/14) |
| Objective response rate | 28.0% (7/25) | 27.3% (3/11) | 28.6% (4/14) |
| R0 resection rate | 82.6% (19/23) | 100.0% (11/11) | 72.7% (8/12) |
| CPR rate | 15.8% (3/19) | 18.2% (2/11) | 12.5% (1/8) |
| MPR rate | 26.3% (5/19) | 36.4% (4/11) | 12.5% (1/8) |
| PPR + rate | 42.1% (8/19) | 45.5% (5/11) | 37.5% (3/8) |
| TRG 1a | 15.8% (3/19) | 18.2% (2/11) | 12.5% (1/8) |
| TRG 1b | 10.5% (2/19) | 18.2% (2/11) | 0 (0/8) |
| TRG 1a/b | 26.3% (5/19) | 36.4% (4/11) | 12.5% (1/8) |
| TRG 2 | 21.1% (4/19) | 18.2% (2/11) | 25.0% (2/8) |
| TRG 3 | 52.6% (10/19) | 45.5% (5/11) | 62.5% (5/8) |
TRG grades were accessed according to the Becker TRG system. CPR complete pathological response, MPR major pathological response, PPR partial pathological response, TRG tumor regression grading.